These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 27745954)

  • 41. Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.
    Miller NC; Quenee LE; Elli D; Ciletti NA; Schneewind O
    Infect Immun; 2012 Apr; 80(4):1572-82. PubMed ID: 22252870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
    Wang S; Goguen JD; Li F; Lu S
    Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.
    Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
    Vaccine; 2008 Nov; 26(50):6329-37. PubMed ID: 18832004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral vaccination against plague using Yersinia pseudotuberculosis.
    Demeure CE; Derbise A; Carniel E
    Chem Biol Interact; 2017 Apr; 267():89-95. PubMed ID: 27046452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen.
    Chiuchiolo MJ; Boyer JL; Krause A; Senina S; Hackett NR; Crystal RG
    J Infect Dis; 2006 Nov; 194(9):1249-57. PubMed ID: 17041851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protection Induced by Oral Vaccination with a Recombinant
    Majumder S; Olson RM; Singh A; Wang X; Li P; Kittana H; Anderson PE; Anderson DM; Sun W
    Infect Immun; 2022 Aug; 90(8):e0016522. PubMed ID: 35900096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Different strategies for preparation of non-tagged rV270 protein and its efficacy against Yersinia pestis challenge.
    Wang W; Qi ZZ; Zhang QW; Wu BC; Zhu ZW; Yang YH; Cui BZ; Dai RX; Qiu YF; Wang ZY; Guo ZB; Shi TX; Wang H; Yang RF; Wang XY
    Biomed Environ Sci; 2010 Oct; 23(5):333-40. PubMed ID: 21112480
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection.
    Okan NA; Mena P; Benach JL; Bliska JB; Karzai AW
    Infect Immun; 2010 Mar; 78(3):1284-93. PubMed ID: 20065026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.
    Bhattacharya D; Mecsas J; Hu LT
    Vaccine; 2010 Nov; 28(48):7683-9. PubMed ID: 20875494
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.
    Gupta A; Narayan B; Kumar S; Verma SK
    Front Immunol; 2020; 11():988. PubMed ID: 32595634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
    Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague.
    Davies ML; Biryukov SS; Rill NO; Klimko CP; Hunter M; Dankmeyer JL; Miller JA; Shoe JL; Mlynek KD; Talyansky Y; Toothman RG; Qiu J; Bozue JA; Cote CK
    Front Immunol; 2024; 15():1397579. PubMed ID: 38835755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague.
    Zvi A; Rotem S; Zauberman A; Elia U; Aftalion M; Bar-Haim E; Mamroud E; Cohen O
    Vaccine; 2017 Oct; 35(44):5995-6006. PubMed ID: 28606812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
    Jones T; Adamovicz JJ; Cyr SL; Bolt CR; Bellerose N; Pitt LM; Lowell GH; Burt DS
    Vaccine; 2006 Mar; 24(10):1625-32. PubMed ID: 16243411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
    Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
    Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.
    Batra L; Verma SK; Nagar DP; Saxena N; Pathak P; Pant SC; Tuteja U
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3322. PubMed ID: 25474358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.
    Levy Y; Flashner Y; Tidhar A; Zauberman A; Aftalion M; Lazar S; Gur D; Shafferman A; Mamroud E
    Vaccine; 2011 Sep; 29(40):6866-73. PubMed ID: 21803090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates.
    Sizemore DR; Warner EA; Lawrence JA; Thomas LJ; Roland KL; Killeen KP
    Hum Vaccin Immunother; 2012 Mar; 8(3):371-83. PubMed ID: 22327496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen.
    Liu WT; Hsu HL; Liang CC; Chuang CC; Lin HC; Liu YT
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):58-69. PubMed ID: 17640293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.